Quest Diagnostics Inc (DGX) 75.81 $DGX
Quest Diagnostics (DGX) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 6:26AM CDT
The following Quest Diagnostics (DGX) conference call took place on April 23, 2015, 08:30 AM ET. This is a transcript of that earnings call:
DGX: 75.81 (+0.60)
Quest Diagnostics posts better Q1 2015 adjusted net income of USD141m
M2 - Fri Apr 24, 5:38AM CDT
Diagnostic information services Quest Diagnostics (NYSE
GX) disclosed on Thursday its adjusted net income of USD141m in first quarter ended 31 March 2015.
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) CEO Steve Rusckowski on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 3:20PM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) Tops Q1 Earnings, Keeps '15 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 10:10AM CDT
Quest Diagnostics' (DGX) first-quarter 2015 adjusted EPS of $1.05 exceeded the Zacks Consensus Estimate by 3 cents.
AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60), ADUS: 28.86 (+0.41)
Quest Diagnostics ups revenues 5% in Q1
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 8:43AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) Lag on Q1 Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 7:57AM CDT
Quest Diagnostics (DGX) Lag on Q1 Earnings & Revenues
DGX: 75.81 (+0.60)
Quest Diagnostics Incorporated (DGX) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Apr 23, 7:25AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics beats 1Q profit forecasts
Automated Insights - Thu Apr 23, 6:57AM CDT
MADISON, N.J. (AP) _ Quest Diagnostics Inc. (DGX) on Thursday reported first-quarter profit of $61 million.
DGX: 75.81 (+0.60)
Quest Diagnostics beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 6:06AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics Reports First Quarter 2015 Financial Results
PR Newswire - Thu Apr 23, 6:00AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the first quarter ended March 31, 2015, adjusted net income was $141 million, compared to $122 million in 2014. Adjusted diluted EPS excluding amortization was $1.05 in the quarter, compared to $0.93 in 2014. Amortization expense was $0.09 per diluted share in both years.
DGX: 75.81 (+0.60)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 52.81 (+0.03), BBT: 37.78 (-0.08), LAZ: 55.89 (-0.32), JAH: 52.23 (-0.97), ASPS: 23.24 (+0.76), HSY: 94.63 (-0.30), CAB: 54.19 (-3.13), CFX: 48.31 (-0.86), FAF: 37.83 (+0.76), HP: 74.42 (-0.91), KKR: 23.39 (-0.15), AEP: 57.88 (+0.98), DNKN: 54.03 (+2.52), CLFD: 14.25 (+0.04), DAN: 21.81 (+0.01), ABBV: 66.07 (+1.82), CSL: 99.55 (+0.47), CAT: 84.60 (-0.19), BHE: 24.30 (-0.16), AVT: 43.47 (-0.28), IR: 68.63 (-0.43), COR: 50.35 (+0.52), ALK: 68.30 (+1.96), COL: 97.79 (-0.16), BKU: 33.10 (-0.29), BCC: 37.41 (-0.29), MJN: 97.94 (+1.53), IQNT: 19.31 (+0.94), ERIC: 11.41 (-0.17), DGX: 75.81 (+0.60), ALXN: 180.08 (-4.50), DOW: 51.12 (+0.12), DST: 118.00 (+0.99), MDP: 53.90 (-0.78), MMM: 158.99 (-0.67), GRA: 97.07 (+0.11), FCX: 20.82 (+0.75), CLI: 18.68 (-0.03), DHR: 83.30 (-1.39), FNB: 13.12 (-0.07), LUV: 43.49 (+0.23), DPS: 78.86 (-0.09), IVC: 20.68 (+0.14), GMT: 55.80 (+0.15), JNS: 18.51 (unch), DPZ: 113.96 (+4.73), DLX: 67.37 (-0.17), CMS: 35.16 (+0.15), LTM: 71.46 (+0.02), MDSO: 57.59 (+0.05), LLY: 71.58 (-0.82), BMS: 45.56 (+0.84), EQT: 86.59 (-0.95), MHO: 23.59 (+0.38), BTU: 4.49 (-0.01), GPK: 14.74 (+0.01), BAX: 71.14 (-0.37), EQM: 88.01 (+0.87), BEAV: 61.60 (-0.64), GM: 35.59 (-0.33), HUB.B: 109.32 (-1.00), JCI: 52.48 (-0.42)
Will Quest Diagnostics' (DGX) Earnings Surprise in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 11:20AM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its first-quarter 2015 results before the opening bell on Apr 23.
MYGN: 33.59 (-0.77), DGX: 75.81 (+0.60), LH: 126.93 (+0.55), MRTX: 27.87 (-0.15)
24.1% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Wed Apr 22, 9:23AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on October 22nd, 2014 at $61.01. In approximately 6 months, Quest Diagnostics has returned 24.14% as of today's recent price of $75.74.
DGX: 75.81 (+0.60)
Fitch Affirms Quest Diagnostics' Ratings at 'BBB'; Outlook Stable
Business Wire - Wed Apr 22, 8:34AM CDT
Fitch Ratings has affirmed the ratings of Quest Diagnostics Inc. (Quest; NYSE: DGX) at 'BBB'. The Rating Outlook is Stable.
DGX: 75.81 (+0.60)
Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
PR Newswire - Tue Apr 21, 7:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share(TM), a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers.
DGX: 75.81 (+0.60), LH: 126.93 (+0.55)
ModernGraham Quarterly Valuation Of Quest Diagnostics Inc.
Benjamin Clark - at Seeking Alpha - Fri Apr 17, 12:48AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics' Pharyngitis Test Wins FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:50PM CDT
Quest Diagnostics' (DGX) Simplexa Direct Strep assay scores over other diagnostic testing procedures as it does not require sample extraction to achieve results, thereby saving on time and costs incurred by laboratories conducting such tests.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
FDA Clears the Simplexa(TM) Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
PR Newswire - Wed Apr 15, 11:31AM CDT
Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.
DGX: 75.81 (+0.60)
North American Revenue Cycle Management Market Report 2015-2019 - Integrated RCM & Standalone RCM
M2 - Wed Apr 15, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nd5bfq/north_american) has announced the addition of the "North American Revenue Cycle Management Market By Product, (Integrated RCM, Standalone RCM), By Component, By Deployment (Web-based, On-premise, Cloud-based), By End User (Hospitals, Physicians, Labs) - Forecast to 2019" report to their offering. The North American revenue cycle management system market, by product is segmented into integrated RCM systems and standalone RCM systems, while the market by deployment is further categorized as on-premises, web-based, and cloud-based. On the basis of component, the market is segmented into hardware, software, and services. The applications are web bill pay, web pre-registration, web scheduling, medical necessity alert at registration, medical necessity alert at scheduling, claims attachment rules, claims denial rules, biller's dashboard, EMR documentation for claims, claims remittance updates AR, direct payer claims, EFT transaction, and eligibility transaction with payer among others. The end-users are physicians, ambulatory care solutions, hospitals, and labs. Globally, North America is the largest revenue cycle management (RCM) system market growing at a CAGR of 12.0% from 2014 to 2019. This growth is mainly attributed to decreasing reimbursements in the healthcare industry, reduction of overall healthcare costs, and increasing expenditure on information technology. Healthcare providers in the North American region are undergoing consolidation, and improving the purchasing capacity for RCM solutions in North America. The district health authority Nova Scotia on April 1, 2015, plans to create a new health system structure that unifies nine district authorities into one body. This is expected to improve the demand for healthcare information technology solutions in these markets. Furthermore, initiatives undertaken by governmental bodies, such as Medicare Medicaid, to support and complement the transformation of healthcare industry in the country, and the e-Health initiative to implement healthcare IT solutions are significant factors propelling the growth of the RCM market. However, limited investments in healthcare IT and high cost of RCM solution are factors restraining its market growth. The report provides a detailed competitive landscaping of companies operating in this market. Segment and country-specific company shares, news & deals, mergers & acquisitions, segment specific pipeline products, product approvals, and product recalls of major companies would also be detailed in this report. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 North American Revenue Cycle Management Market, By Product 6 North American Revenue Cycle Management Market, By Component 7 North American Revenue Cycle Management, By Deployment 8 North American Revenue Cycle Management, By End-User 9 North American Revenue Cycle Management Market, By Geography 10 North American Revenue Cycle Management Market: Competitive Landscape 11 North American Revenue Cycle Management Market, By Company - Allscripts Healthcare Solutions, Inc. - Athenahealth, Inc. - Carecloud Corporation - Cerner Corporation - Eclinicalworks, Llc - Epic Systems - GE Healthcare - Kareo, Inc. - Mckesson Corporation - Quest Diagnostics - The SSI Group, Inc. For more information visit http://www.researchandmarkets.com/research/nd...h_american
DGX: 75.81 (+0.60), MDRX: 12.59 (-0.15), CERN: 73.32 (+0.27)
Quest Diagnostics Falls 1.32% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Apr 14, 5:00PM CDT
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $74.43 to a high of $75.82. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $75.47 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 6:26AM CDT
The following Quest Diagnostics (DGX) conference call took place on April 23, 2015, 08:30 AM ET. This is a transcript of that earnings call:
DGX: 75.81 (+0.60)
Quest Diagnostics posts better Q1 2015 adjusted net income of USD141m
M2 - Fri Apr 24, 5:38AM CDT
Diagnostic information services Quest Diagnostics (NYSE
GX) disclosed on Thursday its adjusted net income of USD141m in first quarter ended 31 March 2015. DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) CEO Steve Rusckowski on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 3:20PM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) Tops Q1 Earnings, Keeps '15 View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 10:10AM CDT
Quest Diagnostics' (DGX) first-quarter 2015 adjusted EPS of $1.05 exceeded the Zacks Consensus Estimate by 3 cents.
AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60), ADUS: 28.86 (+0.41)
Quest Diagnostics ups revenues 5% in Q1
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 8:43AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics (DGX) Lag on Q1 Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 7:57AM CDT
Quest Diagnostics (DGX) Lag on Q1 Earnings & Revenues
DGX: 75.81 (+0.60)
Quest Diagnostics Incorporated (DGX) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Apr 23, 7:25AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics beats 1Q profit forecasts
Automated Insights - Thu Apr 23, 6:57AM CDT
MADISON, N.J. (AP) _ Quest Diagnostics Inc. (DGX) on Thursday reported first-quarter profit of $61 million.
DGX: 75.81 (+0.60)
Quest Diagnostics beats by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 6:06AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics Reports First Quarter 2015 Financial Results
PR Newswire - Thu Apr 23, 6:00AM CDT
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the first quarter ended March 31, 2015, adjusted net income was $141 million, compared to $122 million in 2014. Adjusted diluted EPS excluding amortization was $1.05 in the quarter, compared to $0.93 in 2014. Amortization expense was $0.09 per diluted share in both years.
DGX: 75.81 (+0.60)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 52.81 (+0.03), BBT: 37.78 (-0.08), LAZ: 55.89 (-0.32), JAH: 52.23 (-0.97), ASPS: 23.24 (+0.76), HSY: 94.63 (-0.30), CAB: 54.19 (-3.13), CFX: 48.31 (-0.86), FAF: 37.83 (+0.76), HP: 74.42 (-0.91), KKR: 23.39 (-0.15), AEP: 57.88 (+0.98), DNKN: 54.03 (+2.52), CLFD: 14.25 (+0.04), DAN: 21.81 (+0.01), ABBV: 66.07 (+1.82), CSL: 99.55 (+0.47), CAT: 84.60 (-0.19), BHE: 24.30 (-0.16), AVT: 43.47 (-0.28), IR: 68.63 (-0.43), COR: 50.35 (+0.52), ALK: 68.30 (+1.96), COL: 97.79 (-0.16), BKU: 33.10 (-0.29), BCC: 37.41 (-0.29), MJN: 97.94 (+1.53), IQNT: 19.31 (+0.94), ERIC: 11.41 (-0.17), DGX: 75.81 (+0.60), ALXN: 180.08 (-4.50), DOW: 51.12 (+0.12), DST: 118.00 (+0.99), MDP: 53.90 (-0.78), MMM: 158.99 (-0.67), GRA: 97.07 (+0.11), FCX: 20.82 (+0.75), CLI: 18.68 (-0.03), DHR: 83.30 (-1.39), FNB: 13.12 (-0.07), LUV: 43.49 (+0.23), DPS: 78.86 (-0.09), IVC: 20.68 (+0.14), GMT: 55.80 (+0.15), JNS: 18.51 (unch), DPZ: 113.96 (+4.73), DLX: 67.37 (-0.17), CMS: 35.16 (+0.15), LTM: 71.46 (+0.02), MDSO: 57.59 (+0.05), LLY: 71.58 (-0.82), BMS: 45.56 (+0.84), EQT: 86.59 (-0.95), MHO: 23.59 (+0.38), BTU: 4.49 (-0.01), GPK: 14.74 (+0.01), BAX: 71.14 (-0.37), EQM: 88.01 (+0.87), BEAV: 61.60 (-0.64), GM: 35.59 (-0.33), HUB.B: 109.32 (-1.00), JCI: 52.48 (-0.42)
Will Quest Diagnostics' (DGX) Earnings Surprise in Q1? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 22, 11:20AM CDT
Quest Diagnostics Inc. (DGX) is scheduled to report its first-quarter 2015 results before the opening bell on Apr 23.
MYGN: 33.59 (-0.77), DGX: 75.81 (+0.60), LH: 126.93 (+0.55), MRTX: 27.87 (-0.15)
24.1% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Wed Apr 22, 9:23AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on October 22nd, 2014 at $61.01. In approximately 6 months, Quest Diagnostics has returned 24.14% as of today's recent price of $75.74. DGX: 75.81 (+0.60)
Fitch Affirms Quest Diagnostics' Ratings at 'BBB'; Outlook Stable
Business Wire - Wed Apr 22, 8:34AM CDT
Fitch Ratings has affirmed the ratings of Quest Diagnostics Inc. (Quest; NYSE: DGX) at 'BBB'. The Rating Outlook is Stable.
DGX: 75.81 (+0.60)
Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
PR Newswire - Tue Apr 21, 7:00AM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share(TM), a novel datashare initiative they co-founded to provide scientists and laboratory organizations around the world with open access to BRCA1 and BRCA2 genetic data. The program's goal is to accelerate research on BRCA gene mutations, particularly variants of uncertain significance, to improve the ability of clinical laboratory diagnostics to predict which individuals are at risk of developing hereditary breast and ovarian cancers.
DGX: 75.81 (+0.60), LH: 126.93 (+0.55)
ModernGraham Quarterly Valuation Of Quest Diagnostics Inc.
Benjamin Clark - at Seeking Alpha - Fri Apr 17, 12:48AM CDT
DGX: 75.81 (+0.60)
Quest Diagnostics' Pharyngitis Test Wins FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 12:50PM CDT
Quest Diagnostics' (DGX) Simplexa Direct Strep assay scores over other diagnostic testing procedures as it does not require sample extraction to achieve results, thereby saving on time and costs incurred by laboratories conducting such tests.
CHE: 123.62 (+0.08), AFAM: 47.11 (+1.80), LHCG: 36.06 (+1.33), DGX: 75.81 (+0.60)
FDA Clears the Simplexa(TM) Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
PR Newswire - Wed Apr 15, 11:31AM CDT
Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit. Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.
DGX: 75.81 (+0.60)
North American Revenue Cycle Management Market Report 2015-2019 - Integrated RCM & Standalone RCM
M2 - Wed Apr 15, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nd5bfq/north_american) has announced the addition of the "North American Revenue Cycle Management Market By Product, (Integrated RCM, Standalone RCM), By Component, By Deployment (Web-based, On-premise, Cloud-based), By End User (Hospitals, Physicians, Labs) - Forecast to 2019" report to their offering. The North American revenue cycle management system market, by product is segmented into integrated RCM systems and standalone RCM systems, while the market by deployment is further categorized as on-premises, web-based, and cloud-based. On the basis of component, the market is segmented into hardware, software, and services. The applications are web bill pay, web pre-registration, web scheduling, medical necessity alert at registration, medical necessity alert at scheduling, claims attachment rules, claims denial rules, biller's dashboard, EMR documentation for claims, claims remittance updates AR, direct payer claims, EFT transaction, and eligibility transaction with payer among others. The end-users are physicians, ambulatory care solutions, hospitals, and labs. Globally, North America is the largest revenue cycle management (RCM) system market growing at a CAGR of 12.0% from 2014 to 2019. This growth is mainly attributed to decreasing reimbursements in the healthcare industry, reduction of overall healthcare costs, and increasing expenditure on information technology. Healthcare providers in the North American region are undergoing consolidation, and improving the purchasing capacity for RCM solutions in North America. The district health authority Nova Scotia on April 1, 2015, plans to create a new health system structure that unifies nine district authorities into one body. This is expected to improve the demand for healthcare information technology solutions in these markets. Furthermore, initiatives undertaken by governmental bodies, such as Medicare Medicaid, to support and complement the transformation of healthcare industry in the country, and the e-Health initiative to implement healthcare IT solutions are significant factors propelling the growth of the RCM market. However, limited investments in healthcare IT and high cost of RCM solution are factors restraining its market growth. The report provides a detailed competitive landscaping of companies operating in this market. Segment and country-specific company shares, news & deals, mergers & acquisitions, segment specific pipeline products, product approvals, and product recalls of major companies would also be detailed in this report. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 North American Revenue Cycle Management Market, By Product 6 North American Revenue Cycle Management Market, By Component 7 North American Revenue Cycle Management, By Deployment 8 North American Revenue Cycle Management, By End-User 9 North American Revenue Cycle Management Market, By Geography 10 North American Revenue Cycle Management Market: Competitive Landscape 11 North American Revenue Cycle Management Market, By Company - Allscripts Healthcare Solutions, Inc. - Athenahealth, Inc. - Carecloud Corporation - Cerner Corporation - Eclinicalworks, Llc - Epic Systems - GE Healthcare - Kareo, Inc. - Mckesson Corporation - Quest Diagnostics - The SSI Group, Inc. For more information visit http://www.researchandmarkets.com/research/nd...h_american
DGX: 75.81 (+0.60), MDRX: 12.59 (-0.15), CERN: 73.32 (+0.27)
Quest Diagnostics Falls 1.32% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Apr 14, 5:00PM CDT
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $74.43 to a high of $75.82. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $75.47 on volume of 2.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. DGX: 75.81 (+0.60)
